Boston-based Dewpoint Therapeutics and Merck will collaborate to develop a novel mechanism for the treatment of HIV by harnessing Dewpoint’s proprietary platform for condensate-based drug discovery.
Blackstone Life Sciences V fund closed at its hard cap of $4.6 billion of total capital commitments, marking the largest life sciences private fund that raised to date.
Kymera Therapeutics entered a strategic collaboration deal with Sanofi focused on developing and commercializing protein degrader therapies that target IRAK4 in immune-inflammatory diseases, such as rheumatoid arthritis.
Kiadis Pharma licensed a previously undisclosed K-NK0004 program to Sanofi covering Kiadis’ proprietary CD38 knock out (CD38KO) K-NK therapeutics for combination with anti-CD38 monoclonal antibodies.
Foghorn Therapeutics entered into a strategic collaboration with Merck to leverage Foghorn’s Gene Traffic Control platform for cancer therapies.
Dragonfly Therapeutics announced a new research collaboration with Bristol Myers Squibb to discover and develop Dragonfly’s novel immunotherapies for multiple sclerosis and neuro-inflammation targets.
Cambridge, Massachusetts-based Carmine Therapeutics inked a research collaboration deal with Japan’s Takeda Pharmaceutical to develop and commercialize non-viral gene therapies for two rare diseases.
Sosei Group entered a discovery collaboration and licensing deal with AbbVie, initially focused on inflammatory and autoimmune diseases.
Sanofi Pasteur and Lexington, Massachusetts-based Translate Bio announced the expansion of an existing collaboration to develop mRNA vaccines for infectious diseases.
Cambridge-based Magenta Therapeutics entered a non-exclusive research and clinical collaboration agreement with Beam Therapeutics.